PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• Palvella Therapeutics, Inc. (PVLA) announced on April 7, 2026 that it posted a corporate presentation to its website.
• The presentation was filed with the SEC as Exhibit 99.1 to the Form 8-K and will be used by company representatives in investor meetings. The filing was signed by CFO Matthew Korenberg.

Key Details

• Filing date: April 7, 2026 (Form 8-K, Item 8.01).
• Exhibit filed: 99.1 — Corporate Presentation of Palvella Therapeutics, Inc., dated April 7, 2026.
• Company contact/filing signature: Matthew Korenberg, Chief Financial Officer.
• The filing also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters

• Posting and filing an investor presentation is a routine disclosure that gives investors direct access to the company’s messaging, strategy, pipeline updates, and timelines as presented by management.
• Investors should review the posted presentation on Palvella’s website (or the Exhibit 99.1 filing) for any new program, clinical, or corporate updates that could affect valuation or near-term expectations.